Christian, Sven
Merz, Claudia
Evans, Laura
Gradl, Stefan
Seidel, Henrik
Friberg, Anders
Eheim, Ashley
Lejeune, Pascale
Brzezinka, Krzysztof
Zimmermann, Katja
Ferrara, Steven
Meyer, Hanna
Lesche, Ralf
Stoeckigt, Detlef
Bauser, Marcus
Haegebarth, Andrea
Sykes, David B
Scadden, David T
Losman, Julie-Aurore
Janzer, Andreas
Article History
Received: 25 October 2018
Revised: 28 February 2019
Accepted: 18 March 2019
First Online: 2 April 2019
Compliance with ethical standards
:
: SC, CM, HS, KB, AF, AE, PL, KZ, HM, RL, DS, MB, AH, SG and AJ are employees of Bayer AG. SC, AH, RL, MB, SG and AJ are stockholders of Bayer AG. SC, CM, KZ, DBS, SF, SG and AJ are listed as inventors of Patent application WO2018/077923. DBS, DTS, DS, HM and AJ are listed as inventors of patent application WO2017/037022. DBS is a co-founder and owns equity in Clear Creek Bio. JAL, DBS, DTS, and LE received research funding from Bayer AG. DTS declares the following additional competing interests: Novartis: sponsored research; Agios: director; equity holder; Fate Therapeutics: consultant, equity holder; Magenta Therapeutics: director; equity holder; consultant; Clear Creek Bio: director; equity holder; consultant; Red Oak Medicines: director; equity holder, consultant; LifeVaultBio: director; equity holder; Fog Pharma: consultant